Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System

BACKGROUND: The U.S. Food and Drug Administration (FDA) released a safety warning of Fournier gangrene (FG), a rare but serious adverse effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors in August 2018. However, existing studies have focused mainly on individual FG case reports. Although se...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yang, Bai, Ziyu, Tang, Yan, Liu, Rongji, Zhao, Bin, Gong, Jian, Mei, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368210/
https://www.ncbi.nlm.nih.gov/pubmed/32695827
http://dx.doi.org/10.1155/2020/3695101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368210/
https://www.ncbi.nlm.nih.gov/pubmed/32695827
http://dx.doi.org/10.1155/2020/3695101

Ejemplares similares